Effect of Statin on Progression of Symptomatic Intracranial Atherosclerosis

Hye-Jin Kim, Eun-Kyung Kim, Sun U. Kwon, Jong S. Kim, Dong-Wha Kang

ABSTRACT: Background: Symptomatic intracranial atherosclerosis (ICAS) is a dynamic disease that frequently progresses. Statins have been shown to have anti-atherosclerotic activity. We therefore investigated whether statins could prevent progression of ICAS.

Methods: This retrospective cohort study assessed 55 patients with acute ischemic stroke and symptomatic ICAS in the middle cerebral or basilar arteries as shown on magnetic resonance angiography (MRA), with follow-up MRA performed more than 1 year after the index stroke. Change in ICAS was classified as progressive, regressive, or stable. Baseline clinical characteristics and risk factor control during follow-up were assessed, and laboratory tests were performed at the time of follow-up MRA. The statin group was defined as patients regularly treated with statins for more than 75% of the follow-up period; the remaining patients were defined as the non-statin group.

Results: At a median follow-up time of 21.8 months (range, 11.8-66.1 months), the statin group consisted of 26 (47.3%) patients and the non-statin group of 29 (52.7%). During follow-up, 6 (10.9%) patients progressed, 14 (25.5%) regressed, and 35 (63.6%) remained stable. Statin treatment was significantly associated with non-progression of ICAS (p=0.024). Two patients in the non-statin group had recurrent strokes. Border-zone infarcts were associated with progression of ICAS (3/6, 50%; p=0.007), whereas risk factors and inflammatory biomarkers were not related to progression.

Conclusions: Treatment with statins may prevent progression of symptomatic ICAS. Prospective randomized controlled trials are required to confirm that statins protect against such progression.

Intracranial atherosclerosis (ICAS) is an important cause of ischemic stroke worldwide, particularly in Asian, African American, and Hispanic populations. The incidence of ischemic events in patients with symptomatic ICAS is almost four-fold greater than in patients with asymptomatic atherosclerosis. Moreover, patients with ICAS are at greater risk of recurrent stroke than are other stroke subtypes, as shown in population-based, natural history, and imaging studies.

Atherosclerosis is a dynamic disease that occasionally shows progression despite control of risk factors. Moreover, such progression may be an important surrogate marker for subsequent ischemic stroke, coronary heart disease, and death. Therefore, not only treating the risk factors but also treating arteries based on plaque burden reduces stroke and cardiovascular events and it has been suggested as a new paradigm in the management of atherosclerosis. Prevention of ICAS progression may be an optimal strategy for secondary stroke prevention in such patients.

Statins have been shown to prevent progression or induce regression of atherosclerosis in the coronary and carotid arteries. Thus, statins may also protect against progression of
ICAS. Little is known, however, about the effects of statin treatment on the natural history of ICAS. We therefore utilized serial magnetic resonance angiography (MRA) to determine whether statin treatment affected progression of symptomatic ICAS.

**Material and Methods**

**Recruitment of patients**

In this retrospective cohort study, consecutive patients who experienced acute ischemic stroke between November 2002 and October 2005 were recruited from the stroke center of the Asan Medical Center, Seoul, South Korea. Patients were included if they had (1) acute ischemic stroke as confirmed by diffusion-weighted imaging (DWI), (2) symptomatic ICAS in the middle cerebral artery (MCA) or basilar artery (BA), defined as stenosis of the MCA or BA on MRA, and (3) acute ischemic lesions within the vascular territory of the stenosed artery that corresponded to the individual neurological deficit.

Patients were excluded if they had (1) intracranial arterial occlusion possibly caused by an embolism, (2) significant cardioembolic sources or tandem vascular lesions (i.e., internal carotid or vertebral stenosis), (3) non-atherosclerotic vasculopathy such as moyamoya disease or vasculitis, (4) malignancy, or (5) any medical condition that precluded magnetic resonance imaging. This study was approved by the Institutional Review Board of the Asan Medical Center. All patients or their legal guardians provided written informed consent at the time of long-term follow-up MRA.

Patient data collected at baseline included demographic factors; risk factors (hypertension, diabetes mellitus, coronary heart disease, hypercholesterolemia and current [current or quit for < six months] cigarette smoking); and stroke severity, as measured by the National Institutes of Health Stroke Scale (NIHSS), at both admission and at discharge. Hypercholesterolemia was defined as prescription of cholesterol-reducing agents, an overnight fasting total cholesterol concentration ≥200 mg/dL, or a low-density lipoprotein cholesterol concentration ≥130 mg/dL.

**Statin treatment**

In line with The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines, acute stroke patients in our center with hypercholesterolemia at baseline (low-density lipoprotein cholesterol ≥130 mg/dL) were treated with statins, with the type and dosage being decided by each attending physician. Compliance with statin treatment was evaluated by chart review and interview at the time of long-term follow-up MRA. Patients who regularly remained on statins for >75% of follow-up time were categorized as the statin group; those who did not were classified as the non-statin group.

**Magnetic Resonance Imaging assessment**

Magnetic resonance imaging (MRI) examinations were performed using a 1.5 Tesla MR imaging unit (Signa, GE Medical Systems) with echo-planar capabilities. Three-dimensional time-of-flight intracranial MRAs (TOF-MRAs) were performed using a repetition time (TR) of 25 milliseconds (msec) and a echo time (TE) of 2 msec, and three-dimensional (3D) contrast-enhanced extracranial MRAs from the aortic arch were obtained after an intravenous bolus injection of 20 mL (3-4 mL/sec) gadopentetate dimeglumine.

Our acute stroke protocol requires patients to undergo two MRA evaluations during the acute stage, once within 24 hours of onset, and next five days after the index stroke. It has been reported that the spontaneous recanalization of embolic occlusion usually occurs within 24 hours and residual significant stenosis on follow-up imaging can be considered as ICAS. Accordingly, we enrolled the patients only if they had evidence of luminal stenosis on the five day follow-up MRA. Long-term follow-up 3D TOF-MRA was performed more than one year after the index stroke. The MRA findings were independently reviewed by an investigator (H-JK) blinded to clinical and other MRI data (except for the side on which the lesion had occurred). For determining stenosis degree in ambiguous cases, final decision was made when two experienced stroke neurologists (H-JK and D-WK) achieved consensus. The degree of ICAS was semi-quantitatively classified into five grades: normal, mild (<50% signal reduction), moderate (≥50% signal reduction), severe (local signal loss with the presence of a distal flow signal), and occluded. Change in the degree of ICAS was classified as progression (worsening of stenosis by ≥1 grade on follow-up MRA), regression (improvement in stenosis by ≥1 grade), or stable.

**Patient follow-up**

Laboratory tests (complete blood count; blood chemistry; lipid profile; and measurements of C-reactive protein, lipoprotein (a), apolipoprotein A1 and B, and electrolytes) were performed; and height, body weight, waist circumference, and functional outcome measured by the modified Rankin Scale (mRS) were determined at the time of follow-up MRA. Risk factor control, type and dosage of medications, and drug compliance during follow-up were evaluated. In addition, each patient and/or caregiver was asked whether clinical events had occurred after discharge from the index stroke admission. Such questions were posed by an independent investigator (E-KK) blinded to clinical and imaging information.

**Data analysis**

Descriptive results of continuous variables are expressed as mean ± standard deviation (SD). Demographics and vascular risk factors at baseline were compared between the statin and non-statin groups, with continuous variables evaluated using Student’s t-test or the Mann-Whitney U test, and categorical variables compared employing the χ² or Fisher’s exact tests, as appropriate. We also compared change in ICAS, clinical recurrence, and laboratory results at the time of follow-up MRA between the two groups. A two-tailed p value <0.05 was defined as statistically significant. All statistical analyses were performed using SPSS for Windows (version 14.0; SPSS Inc., Chicago, IL.).

**Results**

Review of the medical records of the stroke center at the Asan Medical Center screened 698 patients who had intracranial large
artery atherosclerosis confirmed by 5-day MRA over the 3-year study period. Of these, 392 patients who had symptomatic ICAS in the MCA or BA were identified. An additional 90 patients were excluded: 45 with thrombolytic therapy, 45 with interventional recanalization procedure. Among the remaining 302 patients, 9 patients died in the hospital, 150 patients transferred to other hospitals, and 71 patients were excluded due to poor outcomes (mRS 4-5 or comorbidity with other medical diseases). Therefore, 72 patients were eligible and agreed to participate in this study and underwent long-term follow-up MRA. Among them, 17 patients with occlusions on 5-day MRA were excluded because of a ceiling effect. Finally, 55 patients were eligible: 29 (52.7%) were men and 26 (47.3%) women; their median age was 68 years (mean ± SD, 66 ± 10 years; range, 39-87 years). The median time from stroke onset to follow-up MRA was 21.8 months (range 11.8-66.1 months). Twenty-nine patients received statin medications, but three were classified into the non-statin group because of poor compliance. Thus, the statin group contained 26 (47.3%) patients and the non-statin group 29 (52.7%). Of the patients in the statin group, 11 were treated with atorvastatin (10-20 mg/day), 9 with pravastatin (10-20 mg/day), 5 with simvastatin (20 mg/day), and 1 with rosuvastatin (10 mg/day). In the comparison between included and excluded patients, excluded patients had severe stroke symptoms and lower rate of prescription of antiplatelet agents. However, demographics and statin therapy were not different.

Baseline characteristics of the statin and non-statin groups

We observed no differences in demographic features, risk factors, or laboratory or imaging characteristics between the statin and non-statin groups, except that hypercholesterolemia was more frequent in the statin than in the non-statin group (5 vs. 0; p=0.019; Table 1). The two groups did not differ in the number of stenotic vessels or the degree of ICAS, in use of anticoagulation or antiplatelet therapy for prevention of recurrent stroke, or in the number of antiplatelet agents prescribed.

Follow-up findings in the statin and non-statin groups

On follow-up MRA, 6 patients (10.9%) showed progression and 14 (25.5%) showed regression of index ICAS lesions, whereas the remaining 35 (63.6%) were stable. Statin treatment was significantly associated with non-progression of ICAS (p=0.024). Prescription of any statin medication, regardless of compliance, was also significantly related to non-progression (p=0.008). Recurrent ischemic events occurred in two patients in the non-statin group, and both were attributed to pre-existing ICAS. In contrast, no patient in the statin group had a recurrent stroke. Lipid profile indices were significantly reduced in the statin group compared with the non-statin group, whereas other inflammatory biomarkers did not differ between the two groups (Table 2).
Table 1: Baseline characteristics of the statin and non-statin groups

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Statin group (n=26)</th>
<th>Non-statin group (n=29)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>68 (44-87)</td>
<td>67 (39-82)</td>
</tr>
<tr>
<td>Gender (male)</td>
<td>11 (42.3%)</td>
<td>18 (62.1%)</td>
</tr>
<tr>
<td>Risk factors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>24 (92.3%)</td>
<td>23 (79.3%)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>7 (26.9%)</td>
<td>6 (20.7%)</td>
</tr>
<tr>
<td>Coronary heart disease</td>
<td>4 (15.4%)</td>
<td>2 (6.9%)</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>5 (10.2%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Current smoking</td>
<td>8 (30.8%)</td>
<td>15 (51.7%)</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>15 (57.7%)</td>
<td>12 (41.4%)</td>
</tr>
</tbody>
</table>

Laboratory data at admission:
- Leukocytes (×1000/µL): 7.6 (4.7-12.0) vs. 7.5 (5.4-16.4)
- Total cholesterol (mg/dL): 196.0 (123.0-255.0) vs. 156.0 (120.0-221.0)
- LDL (mg/dL): 124.0 (55.0-198.0) vs. 86.0 (58.0-159.0)
- Triglyceride (mg/dL): 136.5 (45.0-266.0) vs. 104.0 (38.0-238.0)
- HDL (mg/dL): 44.0 (23.0-63.0) vs. 47.8 (28.0-69.0)
- Non-HDL (mg/dL): 141.5 (65.0-211.0) vs. 104.0 (70.0-167.0)
- C-reactive protein (mg/dL): 0.28 (0.1-2.67) vs. 0.25 (0.01-1.1)

Stenotic vessel:
- MCA (n=46): 21 (80.8%) vs. 25 (86.2%)
- BA (n=9): 5 (19.2%) vs. 4 (13.8%)

Initial MRA stenosis:
- Mild (n=17): 7 (26.9%) vs. 10 (34.5%)
- Moderate (n=24): 12 (46.2%) vs. 12 (41.4%)
- Severe (n=14): 7 (26.9%) vs. 7 (24.1%)

NIHSS score on admission: 4.5 (1-15) vs. 5 (1-14)

Results expressed as number (column %), median (range). LDL = low density lipoprotein, HDL = high density lipoprotein, MCA = middle cerebral artery, BA = basilar artery, NIHSS = National institutes of Health Stroke Scale.

Comparison between the progression and non-progression groups

When we divided patients into those with and without ICAS progression, we observed no differences in patient demographics, risk factors, inflammatory biomarkers during the follow-up period. However, the MRI lesion patterns differed significantly. Small perforator infarcts were more frequently observed in the non-progression group (23/49, 46.9%; p=0.035), whereas single or multiple border-zone infarcts were more often present in the progression group (3/6, 50%; p=0.007).

DISCUSSION

In this observational study evaluating the effects of statins on the natural history of symptomatic ICAS, we found that statin treatment may halt ICAS progression. These findings provide evidence of the beneficial effects of statins on ICAS progression and are in good agreement with the results of studies showing the effects of statins on coronary and carotid atherosclerosis.14,15

Although statins have been shown to exert beneficial effects in stroke patients, as evidenced by a reduction in infarct size and an improvement in cerebral blood flow in animal models19, and prevention of recurrent stroke in humans20,21, the effects of statins on ICAS progression have not been well studied. In a recent Chinese report, statin treatment did not show beneficial effects in patients with asymptomatic ICAS.22 In contrast, another study found that statin treatment resulted in regression of symptomatic ICAS in more than 50% of patients, but this group was not compared with a non-statin-treated group of patients.23 Previous observational studies on the natural history of ICAS have shown progression in 9-32.5% of patients and regression in 7.5-29%.7,8,10,18 Moreover, the annual rate of new ischemic stroke or transient ischemic attack in the territory of the stenosed artery was found to be 15-38.2%.5,24 Recently, the rate of recurrent ischemic stroke or death for the patients receiving intensive medical therapy was shown to be much lower (12.2%) than expected25 and it was suggested that well-controlled risk factors including lipid level or blood pressures might contribute to good outcomes. In the same context, the rate of progression and clinical recurrence was as low as 10.9% and 6.9%. Therefore, it is possible that statin therapy could reduce the risk of subsequent stroke in symptomatic ICAS.

The mechanism underlying the protective effects of statins may be related to the anti-atherogenic properties of the drugs. Despite the fact that our statin group had more frequent hypercholesterolemia and higher lipid profiles than non-statin group, we found that statin treatment had beneficial effects on the progress of symptomatic ICAS. Thus the protective effects of statins may be underestimated in this study, because elevated...
cholesterol levels in symptomatic ICAS patients have been associated with an increased risk of stroke. In terms of anti-inflammatory effects of statin, we found no correlation of C-reactive protein with statin treatment or ICAS progression, although ICAS progression was related to C-reactive protein concentration in a previous report.

Baseline DWI infarct patterns, particularly border-zone infarcts, have been associated with ICAS progression. Border-zone infarcts are related to early neurological deterioration, development of new ischemic lesions, and clinical recurrence in ICAS patients. Thus, border-zone infarcts may indirectly reflect the presence of unfavorable ICAS, such as unstable plaques.

Our study had several limitations. First, the work was a retrospective, small sample sized and non-randomized study. Moreover, not all patients with ICAS were enrolled, resulting in selection bias; patients with severe stroke could not be followed-up, which might underestimate the progression of ICAS or incidence of recurrent stroke. In addition, the time point for follow-up MRA is variable among patients owing to retrospectively collected data. Second, the drug and its dosage were chosen by each physician’s decision and not by standardized protocol, thus introducing bias. Third, we used only MRA to assess progression of ICAS. Additional modalities such as catheter angiography or transcranial Doppler scanning would strengthen the reliability of our results. However, MRA is a non-invasive and well-validated method and the semi-quantitatively MRA grading system showed good correlation with catheter angiography. In addition, we used the upgraded criteria which were applied to previous clinical trials.

In conclusion, statin treatment may have favorable effects on the progression of symptomatic ICAS. Further prospective randomized controlled trials are required to confirm our observations.

Table 2: Follow-up laboratory and imaging findings in the statin and non-statin groups

<table>
<thead>
<tr>
<th>Laboratory findings</th>
<th>Statin group (n=26)</th>
<th>Non-statin group (n=29)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>at follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukocytes (x 1000/µL)</td>
<td>6.8 (3.4-10.1)</td>
<td>5.85 (2.5-11.5)</td>
<td>0.261</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>159.0 (119.0-227.0)</td>
<td>178.0 (139.0-238.0)</td>
<td>0.001</td>
</tr>
<tr>
<td>LDL (mg/dL)</td>
<td>99.0 (48.0-143.0)</td>
<td>120.0 (78.0-186.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Triglyceride (mg/dL)</td>
<td>112.0 (53.0-464.0)</td>
<td>138.0 (39.0-568.0)</td>
<td>0.386</td>
</tr>
<tr>
<td>HDL (mg/dL)</td>
<td>53.0 (38.0-86.0)</td>
<td>51.5 (35.0-82.0)</td>
<td>0.555</td>
</tr>
<tr>
<td>Non-HDL (mg/dL)</td>
<td>109.0 (51.0-187.0)</td>
<td>129.0 (81.0-203.0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Apolipoprotein A1 (mg/dL)</td>
<td>143.6 (106.6-203.1)</td>
<td>136.6 (108.0-190.1)</td>
<td>0.256</td>
</tr>
<tr>
<td>Apolipoprotein B (mg/dL)</td>
<td>69.5 (32.7-120.4)</td>
<td>85.1 (51.7-128.9)</td>
<td>0.001</td>
</tr>
<tr>
<td>Apolipoprotein B/A1 ratio</td>
<td>0.47 (0.2-0.89)</td>
<td>0.63 (0.34-1.0)</td>
<td>0.002</td>
</tr>
<tr>
<td>Lipoprotein (a) (mg/dL)</td>
<td>20.9 (&lt;5.0-171.8)</td>
<td>27.7 (&lt;5.0-114.3)</td>
<td>0.390</td>
</tr>
<tr>
<td>C-reactive protein (mg/dL)</td>
<td>0.12 (0.03-1.11)</td>
<td>0.09 (0.03-2.07)</td>
<td>0.897</td>
</tr>
<tr>
<td>Progression of stenosis (n=6)</td>
<td>0 (0%)</td>
<td>6 (20.7%)</td>
<td>0.024</td>
</tr>
<tr>
<td>Ischemic recurrence (n=2)</td>
<td>0 (0%)</td>
<td>2 (6.9%)</td>
<td>0.492</td>
</tr>
</tbody>
</table>

Results expressed as number (column %), median (range). LDL = low-density lipoprotein, HDL = high-density lipoprotein, MRA = magnetic resonance angiography.

ACKNOWLEDGEMENT

This study was supported by a grant (2011-0538) from the Asan Medical Center, Seoul, Republic of Korea.

REFERENCES